Table 8.11Evidence profile for continuous pump-administered intrathecal baclofen follow-up; upper and lower limb; tone assessment (dystonia)

Number of studiesNumber of participantsEffectQuality
CITBPlaceboRelative

(95% CI)
Absolute

(95% CI)
BADS score 12 months after CITB pump implantation (better indicated by lower values)
1 study (Motta 2008)19a--b-bVery low
Overall BFMS scores 12 months after CITB pump implantation (better indicated by lower values)
1 study (Motta 2008)19c--b-bVery low

BADS Barry–Albright Dystonia Scale, BFMS Burke–Fahn–Marsden Scale, CI confidence interval, CITB continuous pump-administered intrathecal baclofen, NS not (statistically) significant, P probability, SD standard deviation

a

Assessment was conducted pre-implant and at 12 months post-implant by the same team of two rehabilitation therapists and same orthopaedic physician. Overall BAD scores (mean, SD) significantly improved at 12 months when compared with baseline ([mean, SD] 12 months: 17.79 ± 3.3 versus baseline: 23.84 ± 4.11; P < 0.001). Individual BAD scores were not reported for each region, only P values for change. Dystonia significantly improved at 12 months when compared with baseline in all body regions assessed (eyes: < 0.05; mouth: < 0.01, neck: < 0.001, upper limb R: < 0.001, upper limb L: < 0.001, trunk: < 0.001, lower limb R: < 0.01, lower limb L: < 0.01)

b

No statistical comparison was given across groups

c

Overall BFM scores – movement components significantly improved at 12 months when compared with baseline ([mean, SD]: 12 months: 77.60 ± 20.56 versus baseline: 98.57 ± 13.07; P < 0.001). Individual BFM scores – movement components were not reported for each region, only P values for change. Dystonia significantly improved at 12 months when compared with baseline in all body regions assessed except in the eyes and the language swallowing area (eyes: NS, mouth < 0.05; language–swallowing NS; neck < 0.05; upper limb R < 0.05; upper limb L < 0.05; trunk < 0.001; lower limb R < 0.001; lower limb L < 0.001)

See the complete GRADE Table K.8.11 which accompanies this abbreviated version.

From: 8, Intrathecal baclofen

Cover of Spasticity in Children and Young People with Non-Progressive Brain Disorders
Spasticity in Children and Young People with Non-Progressive Brain Disorders: Management of Spasticity and Co-Existing Motor Disorders and Their Early Musculoskeletal Complications.
NICE Clinical Guidelines, No. 145.
National Collaborating Centre for Women's and Children's Health (UK).
London: RCOG Press; 2012 Jul.
Copyright © 2012, National Collaborating Centre for Women's and Children's Health.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.